Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Supportive Care

Between 2014 and 2060, the population of Americans aged ≥65 years is projected to more than double, ushering in a transformation of our workforce, healthcare system, and understanding of aging.1 This generation, and those following, are expected to live longer and remain more active. Every day, the average life span increases by >5 hours, and a growing number of Americans at retirement age choose to continue working full-time.2,3 Unfortunately, with age comes higher rates of chronic illness, including cancer.4 In 2016, individuals aged ≥65 years represented 62% of all 15.5 million cancer survivors in the United States, and by 2040, they are expected to represent 73% of a projected 26.1 million cancer survivors.5
At the 12th Annual New Orleans Summer Cancer Meeting, Jessica MacIntyre, ARNP, NP-C, AOCNP, Director, Clinical Operations, Office of the Director, and Co-Leader, Oncology Nurse Practitioner Fellowship Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, FL, discussed some of the most impactful supportive care abstracts from the 2017 American Society of Clinical Oncology (ASCO) annual meeting, as well as the potential implications of this new research in the field of nursing.
This section provides a quick update of symptomatic conditions in oncology and their management. Readers are invited to submit brief updates following the guidelines at www.JHOPonline.com.
Adolescents and young adults (AYAs) with cancer often wait too long to discuss their end-of-life preferences, or they do not discuss those preferences at all and pass away in a manner that is against their wishes.
Providers caring for dying patients should be prepared to discuss physician-assisted death (PAD).
This section provides a quick update of symptomatic conditions in oncology and their management.
Delaying medication processing is common, especially when it comes to oral cancer therapies. Oncologists at 3 oncology clinics looked at such barriers and the potential impact on patient outcomes.
Most oncologists’ knowledge about toxicities associated with newer therapies comes mainly from clinical trials, but publications of clinical trial safety results may be misleading, according to a study presented by Paolo Bossi, MD, at the recent European Society for Medical Oncology Congress.
Patients receiving allogeneic hematopoietic stem-cell transplant (HSCT) have high rates of vancomycin-resistant enterococci (VRE) upon admission for transplantation.
Adherence to infusional or injectable anticancer drugs is not problematic—as long as the patient gets the infusion or injection, adherence is assured—but adherence is an emerging problem with newer oral anticancer drugs.
Page 1 of 20
Results 1 - 10 of 198